Novavax, Inc. (NVAX)

Last Price:  

Company Description

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $475.60M
Net Income (Most Recent Fiscal Year) $-418.26M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 14.30
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 22.55
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -79.81%
Net Margin (Trailing 12 Months) -80.37%
Return on Equity (Trailing 12 Months) -150.88%
Return on Assets (Trailing 12 Months) -48.19%
Current Ratio (Most Recent Fiscal Quarter) 1.43
Quick Ratio (Most Recent Fiscal Quarter) 1.43
Debt to Common Equity (Most Recent Fiscal Quarter) 0.45
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $9.85
Earnings per Share (Most Recent Fiscal Quarter) $-4.75
Earnings per Share (Most Recent Fiscal Year) $-7.27
Diluted Earnings per Share (Trailing 12 Months) $-13.71
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 74.48M
Free Float 72.92M
Market Capitalization $16.90B
Average Volume (Last 20 Days) 3.79M
Beta (Past 60 Months) 1.62
Percentage Held By Insiders (Latest Annual Proxy Report) 2.10%
Percentage Held By Institutions (Latest 13F Reports) 52.46%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%